These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 27706599

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. MicroRNA-17/20a inhibits glucocorticoid-induced osteoclast differentiation and function through targeting RANKL expression in osteoblast cells.
    Shi C, Qi J, Huang P, Jiang M, Zhou Q, Zhou H, Kang H, Qian N, Yang Q, Guo L, Deng L.
    Bone; 2014 Nov; 68():67-75. PubMed ID: 25138550
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway.
    Zhao C, Sun W, Zhang P, Ling S, Li Y, Zhao D, Peng J, Wang A, Li Q, Song J, Wang C, Xu X, Xu Z, Zhong G, Han B, Chang YZ, Li Y.
    RNA Biol; 2015 Nov; 12(3):343-53. PubMed ID: 25826666
    [Abstract] [Full Text] [Related]

  • 6. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.
    Biochem Pharmacol; 2013 Sep 15; 86(6):782-90. PubMed ID: 23928189
    [Abstract] [Full Text] [Related]

  • 7. Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo.
    Yonezawa T, Hasegawa S, Asai M, Ninomiya T, Sasaki T, Cha BY, Teruya T, Ozawa H, Yagasaki K, Nagai K, Woo JT.
    Eur J Pharmacol; 2011 Jan 15; 650(2-3):511-8. PubMed ID: 21047508
    [Abstract] [Full Text] [Related]

  • 8. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
    Kim HN, Ha H, Lee JH, Jung K, Yang D, Woo KM, Lee ZH.
    Eur J Pharmacol; 2009 Nov 25; 623(1-3):22-9. PubMed ID: 19766111
    [Abstract] [Full Text] [Related]

  • 9. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X, Li Z, Yang Z, Zheng C, Jing J, Chen Y, Ye X, Lian X, Qiu W, Yang F, Tang J, Xiao J, Liu M, Luo J.
    J Bone Miner Res; 2012 Jun 25; 27(6):1298-1308. PubMed ID: 22337253
    [Abstract] [Full Text] [Related]

  • 10. Estrogen inhibits osteoclasts formation and bone resorption via microRNA-27a targeting PPARγ and APC.
    Guo L, Chen K, Yuan J, Huang P, Xu X, Li C, Qian N, Qi J, Shao Z, Deng L, He C, Xu J.
    J Cell Physiol; 2018 Jan 25; 234(1):581-594. PubMed ID: 30272823
    [Abstract] [Full Text] [Related]

  • 11. MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice.
    Kim HN, Lee JH, Jin WJ, Ko S, Jung K, Ha H, Lee ZH.
    Eur J Pharmacol; 2012 Sep 15; 691(1-3):69-76. PubMed ID: 22846626
    [Abstract] [Full Text] [Related]

  • 12. Osteoclast-specific Dicer gene deficiency suppresses osteoclastic bone resorption.
    Mizoguchi F, Izu Y, Hayata T, Hemmi H, Nakashima K, Nakamura T, Kato S, Miyasaka N, Ezura Y, Noda M.
    J Cell Biochem; 2010 Apr 01; 109(5):866-75. PubMed ID: 20039311
    [Abstract] [Full Text] [Related]

  • 13. MicroRNA-29a represses osteoclast formation and protects against osteoporosis by regulating PCAF-mediated RANKL and CXCL12.
    Lian WS, Ko JY, Chen YS, Ke HJ, Hsieh CK, Kuo CW, Wang SY, Huang BW, Tseng JG, Wang FS.
    Cell Death Dis; 2019 Sep 23; 10(10):705. PubMed ID: 31543513
    [Abstract] [Full Text] [Related]

  • 14. miR-31 controls osteoclast formation and bone resorption by targeting RhoA.
    Mizoguchi F, Murakami Y, Saito T, Miyasaka N, Kohsaka H.
    Arthritis Res Ther; 2013 Sep 23; 15(5):R102. PubMed ID: 24004633
    [Abstract] [Full Text] [Related]

  • 15. Expression profiling of microRNAs in RAW264.7 cells treated with a combination of tumor necrosis factor alpha and RANKL during osteoclast differentiation.
    Kagiya T, Nakamura S.
    J Periodontal Res; 2013 Jun 23; 48(3):373-85. PubMed ID: 23078176
    [Abstract] [Full Text] [Related]

  • 16. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H, Härkönen PL, Väänänen HK, Hentunen TA.
    J Bone Miner Res; 2005 Dec 23; 20(12):2224-32. PubMed ID: 16294275
    [Abstract] [Full Text] [Related]

  • 17. miR-145-5p Increases Osteoclast Numbers In Vitro and Aggravates Bone Erosion in Collagen-Induced Arthritis by Targeting Osteoprotegerin.
    Chen Y, Wang X, Yang M, Ruan W, Wei W, Gu D, Wang J, Guo X, Guo L, Yuan Y.
    Med Sci Monit; 2018 Jul 30; 24():5292-5300. PubMed ID: 30059491
    [Abstract] [Full Text] [Related]

  • 18. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
    Moon HJ, Ko WK, Jung MS, Kim JH, Lee WJ, Park KS, Heo JK, Bang JB, Kwon IK.
    J Food Sci; 2013 May 30; 78(5):H785-891. PubMed ID: 23582186
    [Abstract] [Full Text] [Related]

  • 19. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP.
    J Bone Miner Res; 2005 Sep 30; 20(9):1659-68. PubMed ID: 16059637
    [Abstract] [Full Text] [Related]

  • 20. Intravenously delivered glucocorticoid liposomes inhibit osteoclast activity and bone erosion in murine antigen-induced arthritis.
    Hofkens W, Grevers LC, Walgreen B, de Vries TJ, Leenen PJ, Everts V, Storm G, van den Berg WB, van Lent PL.
    J Control Release; 2011 Jun 30; 152(3):363-9. PubMed ID: 21396411
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.